Absci Corporation (ABSI)
3.19
0.06 (1.92%)
At close: Apr 28, 2025, 3:59 PM
3.19
-0.16%
After-hours: Apr 28, 2025, 05:20 PM EDT
1.92% (1D)
| Bid | 3.15 |
| Market Cap | 406.89M |
| Revenue (ttm) | 4.53M |
| Net Income (ttm) | -103.11M |
| EPS (ttm) | -0.94 |
| PE Ratio (ttm) | -3.4 |
| Forward PE | -4.93 |
| Analyst | Buy |
| Ask | 3.19 |
| Volume | 1,404,845 |
| Avg. Volume (20D) | 4,224,375 |
| Open | 3.13 |
| Previous Close | 3.13 |
| Day's Range | 3.10 - 3.25 |
| 52-Week Range | 2.01 - 6.33 |
| Beta | 2.24 |
About ABSI
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington....
Industry Biotechnology
Sector Healthcare
IPO Date Jul 22, 2021
Employees 156
Stock Exchange NASDAQ
Ticker Symbol ABSI
Website https://www.absci.com
Advertisement
Analyst Forecast
According to 5 analyst ratings, the average rating for ABSI stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 181.69% from the latest price.
Stock ForecastsNext Earnings Release
Absci Corporation is scheduled to release its earnings on May 13, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 weeks ago
+22.76%
Shares of healthcare technology stocks are trading...
Unlock content with
Pro Subscription
1 month ago
-4.05%
Absci shares are trading lower after the company reported worse-than-expected Q4 financial results.
